FDA is poised to decide whether to approve the first mRNA flu vaccine

The FDA will soon decide whether to approve the first flu vaccine that uses the same mRNA technology as COVID-19 shots. Health Secretary Robert F. Kennedy Jr. has long questioned mRNA vaccines.

The top 3

  1. Cancer Immunotherapy: Pioneering Personalized Treatments: Personalized mRNA cancer vaccines, like Moderna and Merck's mRNA-4157, have shown promising results in Phase 2 trials for melanoma, reducing recurrence or death by 44% when combined with Keytruda. BioNTech also has a diversified oncology pipeline with over 20 clinical programs, including mRNA cancer immunotherapies for various solid tumors.
  2. RSV and Other Infectious Diseases: Promising Phase 3 Results: Moderna's mRNA-1345 RSV vaccine (mRESVIA) received global regulatory approval in 2024, becoming the first non-COVID mRNA vaccine to do so, demonstrating 68.4% efficacy in a Phase 3 trial for adults aged 60 and older. mRNA technology is also being explored for HIV, with several candidates in clinical trials aiming to elicit broadly neutralizing antibodies.
  3. Autoimmune Disorders: Early Stage Therapeutic Potential: Early-stage studies suggest mRNA therapy could be useful for treating neurodegenerative diseases like Alzheimer's and Parkinson's, and some researchers believe mRNA could help regulate immune responses in conditions like multiple sclerosis and rheumatoid arthritis.

Sources

Open the full topic